Developed and manufactured by Sinovac, Anflu is said to be the only split influenza vaccine produced without preservatives in China. Sinovac is undertaking the sales and marketing program utilizing its established sales force to promote the adult dosage form of Anflu.
Utilizing the virus strain for the northern hemisphere recommended by the World Health Organization, Sinovac has commenced the production of Anflu for the annual flu season based on its 2008-2009 production plan.
Weidong Yin, chairman, president and CEO, said: “We are very pleased to launch Anflu in China for the 2008 – 2009 seasonal influenza season. By utilizing our production capability, we are well positioned to deliver our adult dosage formulation to our target market in China.”